Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain

NACompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 17, 2022

Primary Completion Date

October 16, 2024

Study Completion Date

December 12, 2024

Conditions
Neuropathy, DiabeticNeuropathy;PeripheralNeuropathy, Painful
Interventions
DEVICE

Erchonia® EVRL™

The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.

DEVICE

Placebo Laser

The Placebo Laser has the same appearance as the Erchonia® EVRL™ but does not emit any therapeutic light. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.

Trial Locations (4)

33025

FRANCO & CO Podiatric Medicine & Surgery, Miramar

34698

Cesar A. Lara M.D. Weight Loss & Wellness, Dunedin

85028

CiC Foot & Ankle, Phoenix

91790

Laser Chiropractic, West Covina

Sponsors
All Listed Sponsors
lead

Erchonia Corporation

INDUSTRY